Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

Octreotide is used to treat severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors (such as carcinoid tumors, vasoactive intestinal peptide tumors) that are ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

Significant increases in biochemical response rates were observed in the overall population and in new patients. Treatment with CAM2029, an investigational once-monthly octreotide subcutaneous (SC) ...

The first generic version of Sandostatin ® LAR Depot is now available from Teva Pharmaceuticals. Teva’s Octreotide Acetate for Injectable Suspension is indicated for treatment in patients who have ...

Researchers at the Medical University of South Carolina revealed the need to clarify current treatment guidelines for octreotide therapy following an esophageal variceal hemorrhage in a recent study ...

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...

Small cell carcinoma and large cell neuroendocrine carcinoma of colon and rectum: Incidence, survival outcomes, and comparison with well-differentiated neuroendocrine tumors (NETs) and adenocarcinoma.

MUMBAI, Aug 17 (Reuters) - Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration to make and market octreotide injection, the ...